1.38
-0.02(-1.43%)
Currency In USD
| Previous Close | 1.4 |
| Open | 1.41 |
| Day High | 1.41 |
| Day Low | 1.31 |
| 52-Week High | 4.08 |
| 52-Week Low | 1.31 |
| Volume | 4.53M |
| Average Volume | 4.25M |
| Market Cap | 366.21M |
| PE | -17.25 |
| EPS | -0.08 |
| Moving Average 50 Days | 1.68 |
| Moving Average 200 Days | 2.67 |
| Change | -0.02 |
If you invested $1000 in Akebia Therapeutics, Inc. (AKBA) 10 years ago, it would be worth $171.64 as of January 14, 2026 at a share price of $1.38. Whereas If you bought $1000 worth of Akebia Therapeutics, Inc. (AKBA) shares 5 years ago, it would be worth $435.33 as of January 14, 2026 at a share price of $1.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental glomerulosclerosis (FSGS) AKB-097 Phase 2 rare kidney
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
Clinical trial evaluating changes in urine protein-to-creatinine ratio, a widely-accepted endpoint measuring risk reduction of kidney failureCAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmac
Akebia Announces Establishment of Rare Kidney Disease Pipeline
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stim